Penumbra Inc (PEN) Upgraded to Buy by Citigroup
Citigroup upgrades Penumbra Inc (PEN) to Buy, reflecting improved outlook.
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Penumbra Inc.
Last Updated: Dec 11, 2025, 11:34 PM · Source: Finnhub.io
Citigroup upgrades Penumbra Inc (PEN) to Buy, reflecting improved outlook.
Insider Roberts Johanna sold 64,736 shares of Penumbra Inc (PEN) for $19.42 million.
Insider Bose Arani sold 275,261 shares of Penumbra Inc (PEN) for $82.63M.
Penumbra Inc (PEN) exceeded Q3 2025 earnings expectations.